July 8, 5 p.m., Parks & Recreation Committee
July 13, 7 p.m. Planning Commission
July 14, 3 p.m. Cemetery Commission
Aug. 2, 7 p.m. City Council
Cass County Board of Commissioners
Meets 9 a.m. Tuesday, July 6
Commissioners Board Room
1. 9 a.m. Call to Order
b. Pledge of Allegiance.
c. Approval of agenda for discussion. (Any requests to be heard not on the proposed agenda are considered for inclusion at this time.)
2. 9:05 a.m. Josh Stevenson - County Administrator
a. Consent Agenda
c. Cass County American Rescue Plan Act Grant Funding
d. Establish Public Hearing for Fee Schedule Update
e. Report Back from Solid Waste Committee of the Board
Alabama s community action agencies gather virtually this week for annual conference alabamanewscenter.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from alabamanewscenter.com Daily Mail and Mail on Sunday newspapers.
Poseida Therapeutics Reports Program Updates and Financial Results for the First Quarter 2021
News provided by
Share this article
Share this article
SAN DIEGO, May 11, 2021 /PRNewswire/ Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced program updates and financial results for the first quarter ended March 31, 2021. We are encouraged by our continued progress in first quarter of 2021, building on the accomplishments from the prior year as we moved multiple programs forward to important inflection points, including our ongoing P-BCMA-101 and P-PSMA-101 CAR-T programs, on which we plan to provide further clinical updates later in the year, said Eric Ostertag, M.D., Ph.D., Chief Executive Officer of Poseida. Additionally, we intend to advance two INDs in our allogeneic CAR-T portfolio this year,
Share this article
Share this article
SOUTH SAN FRANCISCO, Calif., May 10, 2021 /PRNewswire/ IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, provided a business update and announced financial results for the first quarter ended March 31, 2021. We are excited to advance IDE397, a potential best-in-class MAT2A inhibitor, in the Phase 1 dose escalation for evaluation in patients with MTAP deletion tumors, including in non-small cell lung cancer (NSCLC). We are also continuing to invest in our preclinical synthetic lethality programs, including our PARG and Pol Theta programs for patients with HRD tumors, where we are targeting a development candidate for both programs in 2021, said Yujiro S. Hata, Chief Executive Officer and President of IDEAYA Biosciences.